Former Teva Generics CEO Siggi Olafsson is back in the copycat game—this time, as new CEO of Jordan’s Hikma Pharmaceuticals.
The company trumpeted the appointment Tuesday, noting that current CEO Said Darwazah would slide over into the executive chairman’s spot. In a statement, Darwazah praised Olafsson’s “deep sector knowledge” and “proven ability to drive growth,” adding that “we are delighted that Siggi is joining Hikma as our new CEO.”
In a major—and unwelcome—surprise to Teva shareholders, Olafsson left his long-held post at the Israeli company in December 2016.
The news stirred up big concerns about the drugmaker’s then-recent $40.5 billion purchase of Allergan’s generics unit. After all, Olafsson had been “a champion” of that deal, Credit Suisse analyst Vamil Divan said at the time.
Turns out that concern was warranted. Pricing pressure mounted on the generics sector, and Teva got hit hard.
Olafsson’s was just the first in a string of executive departures that continued throughout 2017, culminating in a revamped executive structure engineered by new CEO Kåre Schultz. And that revamp eliminated Dipankar Bhattacharjee, Olafsson’s replacement.
Meanwhile, Hikma’s investors celebrated the CEO switch Tuesday, though Jefferies analyst James Vane-Tempest cautioned in a note to clients that “any improvements are likely to be gradual.”
“2018 in our view is still likely to be tough,” he wrote, adding that Hikma “is still challenged by near-term headwinds, and we believe that full-year results on March 14 could disappoint for a number of reasons.”
A couple of those reasons? More competition in generic injectables and the “potential for larger write-downs” at recent buy Roxane Labs.
Investors are also still waiting for word on Hikma’s copy of GlaxoSmithKline respiratory heavyweight Advair after the November news that Hikma and partner Vectura were locked in a dispute with the FDA. An update is expected later this quarter.
By Carly Helfand
Source: Fierce Pharma
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
